ter Haar ELM, van den Reek JMPA, Gaarn Du Jardin K, Barbero-Castillo A, de Jong EMGJ, Lubeek SFK. Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks. Acta Derm Venereol [Internet]. 2023 Oct. 25 [cited 2024 Aug. 16];103:adv17752. Available from: https://medicaljournalssweden.se/actadv/article/view/17752